Viridian Therapeutics, Inc. Common Stock (VRDN) is a publicly traded Healthcare sector company. As of September 22, 2026, VRDN trades at $21.65 with a market cap of $2.49B and a P/E ratio of 0.00. VRDN moved +0.34% today. Year to date, VRDN is -30.66%; over the trailing twelve months it is +11.07%. Its 52-week range spans $9.90 to $34.29. Analyst consensus is strong buy with an average price target of $33.50. Rallies surfaces VRDN's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.
13 analysts cover VRDN: 0 strong buy, 13 buy, 0 hold, 0 sell, and 0 strong sell. The consensus rating is strong buy. The average price target is $33.50.
| Metric | Value |
|---|---|
| Price | $21.65 |
| Market Cap | $2.49B |
| P/E Ratio | 0.00 |
| EPS | $0.00 |
| Dividend Yield | 0.00% |
| 52-Week High | $34.29 |
| 52-Week Low | $9.90 |
| Volume | 6 |
| Avg Volume | 0 |
| Revenue (TTM) | $70.85M |
| Net Income | $-342.60M |
| Gross Margin | 0.00% |
13 analysts cover VRDN: 0 strong buy, 13 buy, 0 hold, 0 sell, 0 strong sell. Consensus rating is strong buy. Average price target: $33.50.